Timely achievement of glycaemic control is key to optimising clinical outcomes. Clinical inertia is most pronounced at the intensification with insulin stage. The NICE guidelines on type 2 diabetes do not explicitly address clinical inertia. Barriers to treatment intensification span patient, clinician and system levels. Clinical inertia can be tackled with increased education on therapeutic options.